STOCK TITAN

Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Benitec Biopharma (BNTC) reported a wider first-quarter fiscal 2027 net loss alongside interim clinical results showing a 100% BB-301 responder rate. Net loss for the quarter ended September 30, 2026, was $12.925 million, versus $8.965 million a year earlier; loss per share widened to $0.26 from $0.22. Research and development expenses rose to $8.618 million from $3.370 million, while administrative expenses fell to $5.859 million from $6.433 million. Cash and cash equivalents totaled $176.368 million, down from $179.972 million at June 30.

The BB-301 results cover six low-dose and three high-dose patients with OPMD-related swallowing difficulty. No serious adverse events have occurred in treated patients to date. Benitec expects to confirm the pivotal study design in the first calendar quarter of 2027 and remains on track to begin the trial in mid-2027. It also plans to change its fiscal year-end from June 30 to December 31.

Loading...
Loading translation...
5 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 6 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Benitec expects pivotal study design confirmation in first-quarter calendar 2027 and trial initiation in mid-2027.
  • Minor pointBB-301 interim results showed a 100% responder rate across six low-dose and three high-dose patients.
  • Minor pointBB-301 treatment has produced no serious adverse events in any treated patient to date.
  • Minor pointGeneral and administrative expenses fell to $5.859 million from $6.433 million in the year-earlier quarter.
  • Minor pointQuarterly net interest income increased to $1.576 million from $1.011 million a year earlier.

Negative

  • Moderate pointQuarterly net loss widened to $12.925 million from $8.965 million; per-share loss increased to $0.26 from $0.22.
  • Moderate pointResearch and development expenses increased to $8.618 million from $3.370 million in the year-earlier quarter.
  • Minor pointCash and cash equivalents declined to $176.368 million at September 30 from $179.972 million at June 30, 2026.
  • Minor pointTotal liabilities increased to $9.451 million at September 30 from $5.610 million at June 30, 2026.
  • Minor pointStockholders’ equity declined to $169.647 million at September 30 from $177.013 million at June 30, 2026.
  • Minor pointCommon shares outstanding increased to 34,889,313 at September 30 from 34,416,834 at June 30, 2026.

News Explained

The September 30 balance sheet reports Benitec common shares issued and outstanding increased from 34,416,834 at June 30, 2026 to 34,889,313 at September 30, 2026; for holders whose share counts did not change, that lowers their proportional ownership.

Key Figures

Responder rate: 100% Total expenses: $14.5 million vs. $9.8 million Net loss: $12.9 million vs. $9.0 million +4 more
Responder rate
100%
BB-301 Phase 1b/2a interim results across Cohorts 1 and 2
Total expenses
$14.5 million vs. $9.8 million
Quarter ended September 30, 2026 vs. September 30, 2025
Net loss
$12.9 million vs. $9.0 million
Quarter ended September 30, 2026 vs. September 30, 2025
Net loss per share
$(0.26) vs. $(0.22)
Basic and diluted, quarter ended September 30, 2026 vs. September 30, 2025
Cash and cash equivalents
$176.5 million
As of September 30, 2026
Pivotal study design confirmation
First calendar quarter of 2027
BB-301
Pivotal trial start
Mid-2027
BB-301; company says it remains on track

Previous Earnings Reports

1 past event · Latest: Nov 14
Same Type 1 event
  1. Nov 14

    Q1 earnings

    24h Move
    +2.8%

    Reported 100% response among Cohort 1 patients and FDA Fast Track designation for BB-301.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

siRNAs, orphan drug designation, fast track designation
3 terms
siRNAs medical
"two small inhibitory RNAs (siRNAs) against mutant PABPN1"
Small interfering RNAs (siRNAs) are short strands of genetic material designed to bind and silence specific genes, like sending a targeted "mute" command to a particular instruction in a cell. Investors care because siRNA-based therapies can precisely treat diseases by turning off harmful genes, offering potential for strong clinical benefits and revenue but also carrying scientific, regulatory and manufacturing risks that affect a biotech company’s value.
orphan drug designation regulatory
"received Orphan Drug Designation from the EMA"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
fast track designation regulatory
"Orphan Drug and Fast Track Designations from the FDA"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients
  • The BB-301 pivotal trial remains on track to begin in mid-2027
  • Well-capitalized with cash, as of September 30, 2026, of approximately $176 million
  • Benitec plans to transition its fiscal year-end for financial reporting from June 30 to December 31. In this release, operational and program guidance is presented on a calendar-year (CY) basis, and financial guidance is presented on a June 30 fiscal-year (FY) basis

HAYWARD, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage biotechnology company developing disease-modifying genetic medicines for life-threatening, genetically defined diseases, based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its first fiscal quarter ended September 30, 2026, and provided an update on recent clinical data presentations.

“This has been a productive period of continued clinical progress for BB-301,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “We recently attended ESGCT and presented the interim clinical results for the three patients enrolled in Cohort 2 and the full clinical results for the six patients enrolled in Cohort 1 that have completed the 12-month study follow-up period. The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia. We are grateful to the patients, families and investigators who have enabled this progress, and we look forward to confirming the pivotal study design in the first calendar quarter of 2027, with the study on track to commence in mid-2027.”

Clinical Highlights

The Company continues to advance BB-301 through clinical development in the ongoing Phase 1b/2a Clinical Study evaluating the safety and clinical efficacy of locally-administered BB-301 for the treatment of OPMD-related dysphagia.

Positive interim clinical results, presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany on October 28, 2026, showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients. There have been no Serious Adverse Events in any patient treated with BB-301 to date.

Upcoming Catalysts

  • Confirmation of the BB-301 pivotal study design in the first calendar quarter of 2027.
  • Benitec is on track to begin the BB-301 pivotal trial in mid-2027.

Financial Highlights

First Quarter 2027 FY Financial Results

Total expenses for the quarter ended September 30, 2026, were $14.5 million compared to $9.8 million for the quarter ended September 30, 2025. The Company incurred $8.6 million of research and development expenses compared to $3.4 million for the comparable quarter ended September 30, 2025. Research and development expenses relate primarily to ongoing clinical development of BB-301 for the treatment of OPMD. General and administrative expenses were $5.9 million compared to $6.4 million for the quarter ended September 30, 2025.

Net loss for the quarter ended September 30, 2026, was $12.9 million compared to a loss of $9.0 million for the quarter ended September 30, 2025. Net loss per basic and diluted share was $(0.26) for the quarter ended September 30, 2026 compared to $(0.22) for the quarter ended September 30, 2025. As of September 30, 2026, the Company had $176.5 million in cash and cash equivalents.

Change in Fiscal Year to Calendar Year

The Company also announced today that it plans to change its existing fiscal year-end from June 30 to December 31 commencing with its first periodic report following the Form 10-Q for the fiscal quarter ended September 30, 2026. In this press release, operational and program guidance is presented on a calendar-year (CY) basis, and historical financial guidance is presented on a June 30 fiscal-year (FY) basis.

About BB-301

BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. BB-301 is administered locally, in a one-time procedure, to the muscles in the throat that drive the swallowing process, an approach designed to maximize local benefit and minimize systemic exposure. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by slowing or halting mutant PABPN1 expression while simultaneously providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA and is currently being evaluated in a Phase 1b/2a, first-in-human, open-label dose escalation study to evaluate the safety and clinical activity of intramuscular doses of BB-301 administered to subjects with OPMD (NCT06185673).

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company developing disease-modifying genetic medicines designed to improve the lives of people with life-threatening, genetically defined diseases. The company’s proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform combines RNA interference, or RNAi, with gene therapy to create medicines designed to facilitate sustained silencing of disease-causing genes and simultaneous delivery of replacement genes that restore normal cellular function following a single administration. The company’s lead investigational candidate, BB-301, is the first and only disease-modifying genetic medicine in clinical development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia. For additional information, visit www.benitec.com.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1993, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of preclinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel adeno-associated viral (AAV) vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of DNA-directed RNA interferences (ddRNAi) and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the U.S. Food and Drug Administration and other governmental authorities; regulatory developments in the United States of America; our ability to protect and enforce our patents and other intellectual property rights; our dependence on our relationships with our collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of our collaboration partners; the acceptance of our products and the products of our collaboration partners in the marketplace and market competition; reliance on third-party manufacturers and suppliers, and the risks associated with manufacturing complexity, supply interruptions, and compliance with current good manufacturing practices; sales, marketing and distribution requirements for our product candidates; greater than expected expenses, including expenses relating to litigation or strategic activities; our incurrence of significant losses and the uncertainty of our ability to achieve or sustain profitability or generate any revenue; our ability to satisfy its capital needs through increasing revenue and obtaining additional financing; the impact of local, regional, national and international economic conditions and events, including geopolitical instability, and risks associated with conducting business and seeking regulatory approvals in international markets; our ability to attract and retain key management, scientific, and technical personnel; cyber-security threats and vulnerabilities in our and our third parties' information technology systems; the impact of legislative and regulatory reforms affecting drug pricing and reimbursement, including Medicare drug-price negotiation and government pricing frameworks; potential product liability claims arising from the use of our product candidates in clinical trials or following any future marketing approval; physicians, patients, third-party payers, or others in the medical community may not be receptive to our product candidates, and we may not generate any future revenue from the sale or licensing of our product candidates; and disruptions to U.S. government agency operations, including FDA staffing changes; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Relations Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com

Media Relations Contact:
Audra Friis
Sam Brown Healthcare Communications
(917) 519-9577
audrafriis@sambrown.com

Source: Benitec Biopharma Inc.


BENITEC BIOPHARMA INC.
Consolidated Balance Sheets
(in thousands, except par value and share amounts)
(Unaudited)

  September 30,
2026
  June 30,
2026
 
Assets      
Current assets:      
Cash and cash equivalents $176,368  $179,972 
Restricted cash  114   114 
Trade and other receivables  —   4 
Prepaid and other assets  1,622   1,595 
Total current assets  178,104   181,685 
Property and equipment, net  110   178 
Deposits  55   55 
Prepaid and other assets  244   12 
Right-of-use assets  585   693 
Total assets $179,098  $182,623 
       
Liabilities and Stockholders’ Equity      
Current liabilities:      
Trade and other payables $7,840  $4,295 
Accrued employee benefits  608   553 
Financing obligation, current portion  122   — 
Lease liabilities, current portion  507   496 
Total current liabilities  9,077   5,344 
Financing obligation, less current portion  239   — 
Lease liabilities, less current portion  135   266 
Total liabilities  9,451   5,610 
       
Stockholders’ equity:      
Preferred stock, $0.0001 par value—5,000,000 shares authorized; no shares issued or outstanding at September 30, 2026 and June 30, 2026, respectively  —   — 
Common stock, $0.0001 par value—160,000,000 shares authorized; 34,889,313 and 34,416,834 shares issued and outstanding at September 30, 2026 and June 30, 2026 respectively  4   3 
Additional paid-in capital  457,237   451,695 
Accumulated deficit  (286,647)  (273,722)
Accumulated other comprehensive loss  (947)  (963)
Total stockholders’ equity  169,647   177,013 
Total liabilities and stockholders’ equity $179,098  $182,623 



BENITEC BIOPHARMA INC.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(Unaudited)

  Three Months Ended 
  September 30, 
  2026  2025 
Operating expenses:      
Research and development  8,618   3,370 
General and administrative  5,859   6,433 
Total operating expenses  14,477   9,803 
Loss from operations  (14,477)  (9,803)
Other income (loss):      
Foreign currency transaction gain (loss)  (23)  (89)
Interest income, net  1,576   1,011 
Other expense, net  (1)  (84)
Total other income, net  1,552   838 
Net loss $(12,925) $(8,965)
Other comprehensive income:      
Unrealized foreign currency translation gain (loss)  16   89 
Total other comprehensive income (loss)  16   89 
Total comprehensive loss $(12,909) $(8,876)
Net loss $(12,925) $(8,965)
Net loss per share:      
Basic and diluted $(0.26) $(0.22)
Weighted average number of shares outstanding:      
Basic and diluted  49,487,369   41,521,280 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Benitec’s BB-301 clinical trial results show?

Interim Phase 1b/2a results showed a 100% responder rate across all Cohort 1 low-dose and Cohort 2 high-dose patients. The results covered six patients in Cohort 1 and three in Cohort 2. No serious adverse events have occurred in any patient treated with BB-301 to date.

When does Benitec expect to start the BB-301 pivotal trial?

Benitec remains on track to begin the BB-301 pivotal trial in mid-2027. The company expects to confirm the pivotal study design in the first calendar quarter of 2027.

What follow-up and study design underpin Benitec’s BB-301 results?

All six low-dose Cohort 1 patients completed the 12-month study follow-up period, while the three high-dose Cohort 2 patients had interim results. The ongoing Phase 1b/2a study is a first-in-human, open-label dose-escalation study evaluating safety and clinical activity in patients with OPMD-related swallowing difficulty.

Keep reading